Valor Capital Group

Valor Capital Group is the cross-border specialist that bridges the United States and Brazil, founded in 2011 by Ambassador Clifford Sobel, a former US Ambassador to Brazil and the Netherlands, and his son Scott Sobel, who serves as Co-founder and Managing Partner. The firm’s deliberately positioned identity as a US-Brazil corridor investor is not marketing; it is the operating thesis. Valor runs distinct vehicles addressing seed through growth, with B Corp certification, IDB Invest as a strategic LP in its Opportunity Fund II vintage, and a portfolio of more than 120 companies including roughly 20 percent of all LatAm unicorns, anchored by Stone, CloudWalk, and Gympass. The cross-border identity matters because it reflects how the partnership runs diligence and supports portfolio companies: deals are evaluated against both Brazilian unit economics and US strategic optionality, and portfolio CEOs routinely use Valor’s New York and Sao Paulo offices to access US institutional capital, US enterprise customers, and US-trained engineering and senior operating talent. For healthcare founders, the relevant fact is that Valor explicitly publishes a healthcare thesis on its website and has built a meaningful digital health and health-tech-enabled portfolio rather than treating the sector as opportunistic. The flagship healthcare bet is TNH Health, the Brazilian AI-powered conversational chatbot company whose Vitalk product targets mental health monitoring through a virtual assistant covering depression, anxiety, stress, and sleep; Valor led TNH’s $2M Series A, one of the largest healthtech Series A rounds in Brazil at the time. TNH was founded in 2013 by Michael Kapps, Juliano Froehner, and Thomas Prufer and runs out of Rio Negrinho, Joinville, and Sao Paulo, and the Vitalk product has reached enterprise distribution through Brazilian employer benefits programs that effectively turn corporate HR budgets into mental-health distribution channels. Sanar, the digital medical education and content platform serving Brazilian medical students and practicing physicians through SanarFlix (a Netflix-style streaming platform for medical education), Sanar Medical Residency for exam preparation, and Sanar Pos for postgraduate courses, anchors the medical workforce and content infrastructure side of the portfolio. Beyond healthcare proper, Valor’s broader portfolio (Loft in real estate, Mimic in dark-kitchen restaurant infrastructure, CargoX in trucking, Cobli in fleet telematics, Olist in commerce, Docket in document automation) telegraphs a preference for tech-enabled services and infrastructure plays in fragmented Brazilian markets, the same archetype that translates well into payer, provider, and pharmacy infrastructure within healthcare. On AI specifically, Valor has signaled that healthcare and AI infrastructure are core 2024-and-beyond priorities, and the published Healthcare Thesis explicitly frames the Brazilian opportunity around the cost burden of the private health system, the digitization gap on the provider side, and the under-served mental health and chronic care segments where conversational AI and digital therapeutics can compound. Stage and check sizing in the $1M to $5M band understates the firm’s actual capacity at growth; Valor co-invests with US growth funds frequently and the Sobels’ US institutional relationships materially expand the cap-table options for portfolio companies as they scale through Series B, Series C, and beyond. The firm leads or co-leads at seed and Series A and tags into US-led growth rounds when its corridor advantage is the differentiator. Scott Sobel sits on multiple healthcare boards directly and has been the most active partner-level voice on the sector, while the broader team brings a mix of US institutional finance and Brazilian operating depth that founders can use to navigate both ANS regulatory questions and US enterprise procurement processes. Founders who fit are Brazilian and LatAm operators building healthcare infrastructure, mental-health and chronic-care digital therapeutics with conversational AI, medical workforce and education platforms, payer and benefits software, and any company whose go-to-market plan benefits materially from a US institutional bridge: fundraising, US-listing optionality, US enterprise customers, US-trained engineering hires, or eventual US-side expansion. Founders who do not fit include pure-Brazil consumer brands without a tech wedge, therapeutics and devices teams (out of scope), and founders who have no need or interest in the US side of the corridor and would extract more value from a Brazil-only specialist. The intro path is via Scott Sobel directly through a warm New York or Sao Paulo introduction, a portfolio CEO from Stone, Gympass, TNH Health, or Sanar, or through Valor’s US LP and co-investor network which is unusually rich for a Brazilian-corridor fund and includes US growth funds, family offices, and policy-aligned institutions like IDB Invest. In the pitch, lead with the corridor advantage and quantify why your wedge benefits from a US-Brazil bridge specifically rather than a Brazil-only thesis; bring regulatory literacy on both ANS and any US-side considerations such as HIPAA or FDA where applicable, and demonstrate that your team can operate across both markets credibly. The caveats: Valor’s identity is genuinely cross-border, founders who do not engage the US side of the relationship under-extract from the partnership, the firm’s check-size discipline at seed means founders chasing aggressive valuations should expect a thoughtful rather than competitive process, and the partnership’s preference for tech-enabled services and infrastructure plays means deeper science or biotech founders are unlikely to find traction.